Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells 8,092 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 8,092 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total value of $75,822.04. Following the sale, the chief financial officer now owns 322,488 shares of the company’s stock, valued at approximately $3,021,712.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Austin Aerts also recently made the following trade(s):

• On Tuesday, February 6th, Austin Aerts sold 9,786 shares of Sera Prognostics stock. The shares were sold at an average price of $8.03, for a total value of $78,581.58.

Sera Prognostics Trading Down 0.4 %

Shares of Sera Prognostics stock opened at $9.46 on Thursday. The stock has a fifty day simple moving average of $8.40 and a 200 day simple moving average of $5.00. Sera Prognostics, Inc. has a 12-month low of $1.52 and a 12-month high of $10.44.

Institutional Investors Weigh In On Sera Prognostics

Institutional investors have recently bought and sold shares of the stock. Frontier Wealth Management LLC bought a new stake in Sera Prognostics during the first quarter worth $30,000. Susquehanna International Group LLP bought a new stake in Sera Prognostics during the first quarter worth $39,000. Goldman Sachs Group Inc. bought a new position in Sera Prognostics in the 1st quarter valued at $41,000. Charles Schwab Investment Management Inc. bought a new position in Sera Prognostics in the 1st quarter valued at $46,000. Finally, Bank of New York Mellon Corp bought a new position in Sera Prognostics in the 1st quarter valued at $50,000. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.